BL-41Homo sapiens (Human)Cancer cell line
Also known as: IARC BL 41, IARC-BL-41, IARC BL41, IARC-BL41, IARC/BL 41, IARC/BL41, BL 041, BL 41, BL41
Quick Overview
BL-41 is a human B-cell lymphoma cell line derived from Burkitt's lymphoma, used in cancer research for studying genetic and mo...
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1087 |
|---|---|
| Species | Homo sapiens (Human) |
Donor Information
| Age | 8 |
|---|---|
| Age Category | Pediatric |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Burkitt lymphoma |
|---|---|
| Lineage | Lymphoid |
| Subtype | Burkitt Lymphoma |
| OncoTree Code | BL |
DepMap Information
| Source Type | DSMZ |
|---|---|
| Source ID | ACH-000245_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Arg248Gln (c.743G>A) | Unspecified | Somatic mutation acquired during proliferation | PubMed=20575032 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Screening human cell lines for viral infections applying RNA-Seq data analysis.
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
PLoS ONE 14:E0210404-E0210404(2019).
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
Yang H.H., Koeffler H.P.
BMC Cancer 18:940.1-940.13(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.
O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.
J. Virol. 89:713-729(2015).
Comprehensive cytogenetic and molecular cytogenetic analysis of 44 Burkitt lymphoma cell lines: secondary chromosomal changes characterization, karyotypic evolution, and comparison with primary samples.
Vettorazzi E., Bokemeyer C., Dierlamm J.
Genes Chromosomes Cancer 53:497-515(2014).
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.
Nature 490:116-120(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.
Int. J. Cancer 125:212-221(2009).
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.
Martinez-Climent J.A.
Blood 109:271-280(2007).
Genome-wide search for loss of heterozygosity in Burkitt lymphoma cell lines.
Eisinger F., Longy M., Romeo G., Lenoir G.M., Birnbaum D.
Genes Chromosomes Cancer 33:217-224(2002).
Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis.
Magrath I.T., Bhatia K.G.
Cancer Res. 59:696-703(1999).
p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma.
Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.
Blood 91:1680-1687(1998).
Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells.
Pike S.E., Gupta G., Magrath I.T., Tosato G.
Cancer Res. 57:2508-2515(1997).
The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.
Quentmeier H., Drexler H.G.
Leukemia 10:142-149(1996).
Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.
Uppenkamp M.J., Nowrousian M.R., Seeber S., Opalka B.
Br. J. Haematol. 91:350-354(1995).
Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin.
Lenoir G.M.
J. Natl. Cancer Inst. 73:841-847(1984).
The use of lymphomatous and lymphoblastoid cell lines in the study of Burkitt's lymphoma.
Lenoir G.M., Vuillaume M., Bonnardel C.
IARC Sci. Publ. 60:309-318(1985).
Immunophenotypic classification of 28 Burkitt cell lines with monoclonal antibodies and reagent selection for bone-marrow purging.
Dore J.-F., Lenoir G.M.
IARC Sci. Publ. 60:447-452(1985).
Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.
Klein G.
Proc. Natl. Acad. Sci. U.S.A. 84:4567-4571(1987).
B-cell maturation stages of Burkitt's lymphoma cell lines according to Epstein-Barr virus status and type of chromosome translocation.
Manel A.-M., Vincent C., Bryon P.-A.
J. Natl. Cancer Inst. 78:235-242(1987).
Expression of B-cell-specific markers in different Burkitt lymphoma subgroups.
Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.
Int. J. Cancer 39:211-218(1987).
Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells.
Lenoir G.M.
Proc. Natl. Acad. Sci. U.S.A. 84:8060-8064(1987).
Reversion of tumorigenicity and decreased agarose clonability after EBV conversion of an IgH/myc translocation-carrying BL line.
Ehlin-Henriksson B., Masucci M.G., Klein G., Klein E.
Int. J. Cancer 43:273-278(1989).